toreforant (JNJ-38518168) / J&J  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
toreforant (JNJ-38518168) / J&J
NCT01679951 / 2011-002840-29: A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Terminated
2b
272
Japan, US, Europe, RoW
Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate
Janssen Research & Development, LLC
Rheumatoid Arthritis
04/14
07/14
NCT00941707 / 2009-012118-27: An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid Arthritis

Terminated
2a
86
Europe, RoW
JNJ 38518168, Placebo
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Rheumatoid Arthritis
11/10
11/10
NCT01823016 / 2012-004920-39: A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma

Completed
2a
166
US, Canada, Europe, RoW
Placebo, JNJ-38518168
Janssen Research & Development, LLC
Asthma
07/15
07/15
NCT01862224: A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Terminated
2
21
US, RoW
JNJ-38518168, Placebo, Methotrexate
Janssen Research & Development, LLC
Rheumatoid Arthritis
07/14
07/14
NCT02295865 / 2015-000277-12: A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

Completed
2
62
US, Europe
JNJ-38518168 60 mg, Toreforant, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo
Janssen Research & Development, LLC
Psoriasis
03/16
03/16

Download Options